Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + methotrexate + ifosfamide + L-asparaginase + etoposide
- Development stage
- Unknown
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Intramuscular, Intrathecal
01
Overview
This is a multi-agent chemotherapy regimen composed of five drugs—dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide—used in the treatment of certain hematologic malignancies such as acute lymphoblastic leukemia (ALL) and lymphomas. Each component has a distinct mechanism of action: - Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. - Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking DNA synthesis. - Ifosfamide is an alkylating agent that crosslinks DNA strands to prevent cell replication. - L-asparaginase depletes asparagine, an amino acid essential for leukemic cell survival. - Etoposide inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. This combination targets cancer cells through multiple pathways to maximize cytotoxicity and reduce resistance. Such regimens are commonly used in induction or consolidation phases for ALL or aggressive lymphomas[5][6][8].
- Other names
- SMILE regimenSMILE protocolSMILE chemotherapyModified SMILEmSMILE
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone + methotrexate + ifosfamide + L-asparaginase + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + methotrexate + ifosfamide + L-asparaginase + etoposide.